| 0.75 | 2.44% |
| SLXP Salix Pharmaceuticals Ltd. | Trade It Now | | NASDAQ |
| |
Market Cap 1.640B Book Value 7.093 EBITDA -27.2M Year Low 8.75 Year High 32.03 PEG Ratio 14.42 EPS -0.884 P/B Ratio 4.33 Short Ratio 3.30 Index Membership S&P 600 SmallCap S&P  Sector Healthcare Industry Drug Related Products Open 30.90 High 31.52 Low 30.70 Last Close 30.68 Volume 2.2 M Target Price 41.33 Current EPS -0.884 This Year EPS 0.05 Next Year EPS 1.48 This Year PE 613.60 Next Year PE 20.73 Salix Pharmaceuticals Ltd.1700 Perimeter Park Drive Morrisville,
NC 27560-8404 United States - Map
Phone: 919-862-1000
Fax: 919-862-1095
Web Site: VisitType: Stock | | Salix Pharmaceuticals, Ltd. acquires, develops, and commercializes prescription drugs for the treatment of gastrointestinal disorders in the United States. |
Company Summary more  Salix Pharmaceuticals, Ltd. acquires, develops, and commercializes prescription drugs for the treatment of gastrointestinal disorders in the United States. The company?s marketing products include Xifaxan tablet, a gastrointestinal-specific oral antibiotic for the treatment of patients with travelers? diarrhea; MoviPrep, a liquid polyethylene glycol-salt bowel cleansing product; Visicol and OsmoPrep tablets for cleansing of the colon as a preparation for colonoscopy in adults; and Apriso, for the maintenance of remission of ulcerative colitis in adults. Its marketing products also include Metozolv ODT orally disintegrating tablets for the relief of symptomatic gastroesophageal reflux or shor... Salix Pharmaceuticals, Ltd. acquires, develops, and commercializes prescription drugs for the treatment of gastrointestinal disorders in the United States. The company?s marketing products include Xifaxan tablet, a gastrointestinal-specific oral antibiotic for the treatment of patients with travelers? diarrhea; MoviPrep, a liquid polyethylene glycol-salt bowel cleansing product; Visicol and OsmoPrep tablets for cleansing of the colon as a preparation for colonoscopy in adults; and Apriso, for the maintenance of remission of ulcerative colitis in adults. Its marketing products also include Metozolv ODT orally disintegrating tablets for the relief of symptomatic gastroesophageal reflux or short-term therapy for adults; Azasan, a drug that suppresses immune system responses and is indicated for preventing rejection of kidney transplants and treatment of severe arthritis; Anusol-HC and Proctocort, the hydrocortisone creams and suppositories for use in inflamed hemorrhoids and postirradiation proctitis, as well as an adjunct in the treatment of chronic ulcerative colitis and inflammatory conditions; Pepcid and Diuril oral suspensions, which are used for gastrointestinal indications that include the treatment of duodenal ulcer, benign gastric ulcer, and gastro esophageal reflux diseases; and Colazal capsules for the treatment of ulcerative colitis. In addition, Salix has products under development for the treatment of hepatic encephalopathy and irritable bowel syndrome, HIV-associated diarrhea, gastroenterology, and ulcerative proctitis or proctosigmoiditis. It has collaboration agreements with aaiPharma LLC; Alfa Wassermann S.P.A.; Biorex Laboratories Limited; Cedars?Sinai Medical Center; Clinical Development Capital Partnership; Dr. Falk Pharma GmbH; King Pharmaceuticals, Inc.; Lupin, Ltd.; Merck & Co., Inc.; Napo Pharmaceuticals, Inc.; Norgine B.V.; and Wilmington Pharmaceuticals, LLC. The company was founded in 1989 and is headquartered in Morrisville, North Carolina. Salix Pharmaceuticals, Ltd. acquires, develops, and commercializes prescription drugs for the treatment of gastrointestinal disorders in the United States. The company?s marketing products include Xifaxan tablet, a gastrointestinal-specific oral antibiotic for the treatment of patients with travelers? diarrhea; MoviPrep, a liquid polyethylene glycol-salt bowel cleansing product; Visicol and OsmoPrep tablets for cleansing of the colon as a preparation for colonoscopy in adults; and Apriso, for the maintenance of remission of ulcerative colitis in adults. Its marketing products also include Metozolv ODT orally disintegrating tablets for the relief of symptomatic gastroesophageal reflux or shor... Top Stories| | 2010-03-17 |  | |
| | | 2010-03-15 |  | |
| | | 2010-03-15 |  | |
| | | 2010-03-15 |  | |
|
| | A rally among airlines and a surprise jump in factory orders pushed US stocks higher in choppy trading on Tuesday. 2010-03-19 |  | |
|
Community Discussions | | | 0.44 | 3.02% |
| NUTR Nutraceutical International Co | Trade It Now | | NASDAQ |
| |
Market Cap 155.9M Book Value 9.421 EBITDA 30.0M Year Low 6.17 Year High 15.67 EPS -1.228 P/B Ratio 1.55 Short Ratio 9.50 Sector Healthcare Full Time Employees 655 Industry Drug Related Products Open 14.57 High 15.06 Low 14.375 Last Close 14.59 Volume 74.2 K Target Price 17.00 Current EPS -1.228 This Year EPS 1.33 Next Year EPS 1.54 This Year PE 10.97 Next Year PE 9.47 Nutraceutical International Corp.1400 Kearns Boulevard 2nd Floor Park City,
UT 84060 United States - Map
Phone: 435-655-6106
Fax: 435-647-3802
Web Site: VisitType: Stock | | Nutraceutical International Corporation engages in the manufacture, marketing, distribution, and retail of branded nutritional supplements and other natural products in the United States and internationally. |
Company Summary more  Nutraceutical International Corporation engages in the manufacture, marketing, distribution, and retail of branded nutritional supplements and other natural products in the United States and internationally. The company offers vitamins and minerals, herbs, specialty formulas, personal care products, homeopathics, functional foods, and other products in various formulations and delivery forms, including capsules, tablets, softgels, chewables, liquids, creams, sprays, powders, and whole herbs. It also publishes, prints, and markets a line of books and booklets to book distributors, national retail bookstores, and health and natural food stores; distributes branded products of certain third par... Nutraceutical International Corporation engages in the manufacture, marketing, distribution, and retail of branded nutritional supplements and other natural products in the United States and internationally. The company offers vitamins and minerals, herbs, specialty formulas, personal care products, homeopathics, functional foods, and other products in various formulations and delivery forms, including capsules, tablets, softgels, chewables, liquids, creams, sprays, powders, and whole herbs. It also publishes, prints, and markets a line of books and booklets to book distributors, national retail bookstores, and health and natural food stores; distributes branded products of certain third parties; and owns neighborhood natural food markets and health food stores. Nutraceutical International sells its products primarily to and through domestic health and natural food stores. The company was founded in 1993 and is based in Park City, Utah. Nutraceutical International Corporation engages in the manufacture, marketing, distribution, and retail of branded nutritional supplements and other natural products in the United States and internationally. The company offers vitamins and minerals, herbs, specialty formulas, personal care products, homeopathics, functional foods, and other products in various formulations and delivery forms, including capsules, tablets, softgels, chewables, liquids, creams, sprays, powders, and whole herbs. It also publishes, prints, and markets a line of books and booklets to book distributors, national retail bookstores, and health and natural food stores; distributes branded products of certain third par... Top Stories| | 2010-03-16 |  | |
| | |
GMP Labs Expands Liquid Nutraceutical Capabilities
PR Web - Mar 11, 2010
GMP Laboratories of America, Inc., a leading custom manufacturer of dietary supplements and homeopathic drugs, has announced that the recent expansion of its production capabilities for various ...
2010-03-11 |  | |
| | | 2010-03-02 |  | |
| | | 2010-03-02 |  | |
|
Community Discussions |